When will Beam Therapeutics submit a BLA for Risto-cel?
22.0 pt (24h)Health & MedicineOne-OffScienza1m
KalshiVerifica disponibilitàKYC richiesto2% di commissioneDati di risoluzione verificatiDiscretamente calibratoProbabilità implicita attuale
before April 2027 93%In testa tra 6 esiti
Qualità del mercato
44 / 100
Bassa qualitàVolume 24h
1K €
Liquidità
16,9K €
Liquidità mediaSpread
84.0 pt
Spread ampioDati di mercato
Aggiornato 10 minuti fa
24 mar 26, 14:00 UTC1 nov 26, 05:00 UTC
Trend
Mercati Correlati
Domande correlate per il contesto, non un confronto tra contratti equivalenti.
FDA decision: Ivonescimab by Summit Therapeutics (in 2026)
KalshiFDA decision: Saroglitazar by Zydus Therapeutics (in 2026)
KalshiWhen will Compass Pathways submit a NDA for COMP360 psilocybin?
KalshiWill we get AGI before 2029?
Manifold MarketsWill we get AGI before 2028?
Manifold MarketsWill we get room temperature superconductors before 2033?
Manifold MarketsRegole
If Beam Therapeutics Inc. submits a BLA for Ristoglogene autogetemcel (risto-cel) to the FDA before Sep 1, 2026, then the market resolves to Yes.
- If Beam Therapeutics Inc. submits a BLA for Ristoglogene autogetemcel (risto-cel) to the FDA before Oct 1, 2026, then the market resolves to Yes.
- If Beam Therapeutics Inc. submits a BLA for Ristoglogene autogetemcel (risto-cel) to the FDA before Nov 1, 2026, then the market resolves to Yes.
- If Beam Therapeutics Inc. submits a BLA for Ristoglogene autogetemcel (risto-cel) to the FDA before Dec 1, 2026, then the market resolves to Yes.
- If Beam Therapeutics Inc. submits a BLA for Ristoglogene autogetemcel (risto-cel) to the FDA before Jan 1, 2027, then the market resolves to Yes.
- If Beam Therapeutics Inc. submits a BLA for Ristoglogene autogetemcel (risto-cel) to the FDA before Apr 1, 2027, then the market resolves to Yes.
Mercati aperti
Health & Medicine
POLYMARKETHantavirus pandemic in 2026?
- No97%
- Yes3%
- Volume totale
- 15,6 Mln €
- Volume 24h
- 18K €
POLYMARKETNew pandemic in 2026?
- No94.1%
- Yes5.9%
- Volume totale
- 920,1K €
- Volume 24h
- 4K €
KALSHIMedtronic cardiovascular growth in Q2
- Above 8%92%
- Above 9%81%
- Above 11.5%53%
+6 altri esiti
- Volume totale
- 2,6K €
- Volume 24h
- 2,6K €
KALSHIMeasles cases in 2026?
- Above 300099%
- Above 4000+1.0pt98%
- Above 6000+2.0pt61%
+2 altri esiti
- Volume totale
- 868,1K €
- Volume 24h
POLYMARKETMeasles cases in U.S. in 2026?
- ↑3.5k100%
- ↑500+0.1pt100%
- ↑1k+0.1pt100%
+9 altri esiti
- Volume totale
KALSHIPandemic in 2026?
- No95%
- Yes5%
- Volume totale
- 612,7K €
- Volume 24h
- 1,2K €
- Which countries will report an Ebola disease case before October?
- What will RFK say during RNC Midterm Convention?
- When will the FDA approve Intellia Therapeutics' lonvo-z?
- Will the FDA approve retatrutide?
- When will Compass Pathways submit a NDA for COMP360 psilocybin?
- Measles cases in U.S. by September 30?
- Will WHO declare Hantavirus a Public Health Emergency of International Concern this Year?
- When will Heidi Overton be confirmed as Commissioner of the FDA?
- How many West Nile neuroinvasive disease cases will be reported among New York City residents in 2026?
- Will 3 mg THC beverages qualify as hemp under federal law?
Domande frequenti
- Quali sono le probabilità attuali per When will Beam Therapeutics submit a BLA for Risto-cel??
- Kalshi quota before April 2027 al 93% al 10 settembre 2026.
- Quando si risolve When will Beam Therapeutics submit a BLA for Risto-cel??
- When will Beam Therapeutics submit a BLA for Risto-cel? dovrebbe risolversi il 1 novembre 2026.
- Come viene liquidato When will Beam Therapeutics submit a BLA for Risto-cel??
- Kalshi liquida questo mercato come segue: If Beam Therapeutics Inc. submits a BLA for Ristoglogene autogetemcel (risto-cel) to the FDA before Sep 1, 2026, then the market resolves to Yes.